Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

Stock Information for Lisata Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lisata Therapeutics Inc.

Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger-PEN, RAPT, NATH, and LSTA
Halper Sadeh LLC Encourages NATH, RAPT, FONR Shareholders to Contact the Firm to Discuss Their Rights
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
Halper Sadeh LLC Encourages CVGW, RAPT, CFLT Shareholders to Contact the Firm to Discuss Their Rights
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq - RAPT), Penumbra, Inc. (NYSE - PEN), Calavo Growers, Inc. (Nasdaq - CVGW), FONAR Corporation (Nasdaq - FONR)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of RAPT Therapeutics, Inc. (NASDAQ: RAPT)
Shareholder Alert: The Ademi Firm investigates whether RAPT Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.